Human cells made easy ™
Elpis BioMed was formed in 2017 as a spin-out from the University of Cambridge.
Based on disruptive technology called "reprogramming", Elpis provides differentiated human cells and tissue models for science, drug discovery, and toxicology.
The application of human cells in the drug discovery process promises to revolutionise translation by
Reducing attrition in drug discovery.
Elpis announces funding round with lead investor Jonathan Milner
Elpis is pleased to announce the successful closing of a funding round. This will enable us to bring our products to market and increase our product pipeline.
Prof. Roger Pedersen, world-acclaimed stem cell scientist, joins Elpis as scientific advisor.
Prof. Pedersen, co-founder of the Cambridge Stem Cell Institute, is word-renowned for his work on pluripotency and differentiation of induced pluripotent cells.